Research on HIV/AIDS Drug Resistance
Overviews
- Predictive Value of HIV-1 Genotypic Resistance Test Interpretation Algorithms (August 1, 2009)
In The Journal of Infectious Diseases
- Nucleoside RT Inhibitor Surveillance Drug Resistance Mutation (SDRM) List: 34 Mutations at 15 Positions (March 6, 2009)
In PLoS ONE
- Natural Variation of HIV-1 Group M Integrase: Implications for a New Class of Antiretroviral Inhibitors (August 7, 2008)
In Retrovirology
- News on HIV Drug Resistance in New Antiretrovirals From the XVI International HIV Drug Resistance Workshop (July 24, 2007)
With every new medication it's critical to understand which mutations are predictive of a less than optimal response. In this report on Doug Richman's review from the XVI International HIV Drug Resistance Workshop, Mark Holodniy, M.D., discusses genotypic and phenotypic assays associated with R5 inhibitors and HIV drug resistance associated with the following antiretrovirals in development: etravirine, raltegravir, elvitegravir and maraviroc.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- New Developments in the Management of HIV Treatment-Naive Patients (February 28, 2007)
Includes an analysis of research examining once-daily regimens, the use of viral decay rate to assess treatment efficacy, and issues related to primary HIV drug resistance.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Baseline NNRTI Resistance and Virologic Failure in Treatment-Naive Patients on Efavirenz: An Interview With Daniel Kuritzkes, M.D. (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Optimizing Therapy for Patients With Multidrug-Resistant HIV (July 31, 2006)
To read PDF, click here
From Insight Medical Communications Inc.
- Survey Reveals Nearly Twice as Many Physicians Than Patients Are Concerned About HIV Drug Resistance (July 18, 2006)
From American Academy of HIV Medicine
- New Developments in HIV Drug Resistance and Options for Treatment-Experienced Patients (May 15, 2006)
Coverage of the 4th European HIV Drug Resistance Workshop and the 12th Annual Conference of the British HIV Association
Free CME/CE credit available for physicians, nurses and pharmacists.
From The Body PRO
- Wall Street Journal Spotlights HIVers With Heavy Drug Resistance (May 3, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Resistance Risk
- Researchers Develop Questions to Determine Risk of HIV/AIDS Drug Resistance (May 19, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Sudden Drop Observed in Transmitted HIV Drug Resistance Among Cohort of Recently Infected San Francisco Patients (February 10, 2009)
Vivek Jain, M.D., presents data from a cohort of 266 patients with acute and early HIV infection, among whom a sudden drop in the prevalence of transmitted HIV drug resistance occurred in 2008 -- dramatically reversing a general upward trend over the previous four years.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Regimens With Boosted Protease Inhibitors Are the Most Resistance-Proof, Study Finds (May 22, 2008)
In The Journal of Infectious Diseases
- Drug Use During Sex May Make Infection With Drug-Resistant HIV More Likely (May 20, 2008)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Consequences of Non-Adherence Worse in African-Americans than White People (December 16, 2007)
From aidsmap.com
- First-Line Triple-Combination Antiretroviral Therapy Provides Long-Term Protection Against AIDS-Related Illnesses, Study Says (December 10, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Drug-Resistant HIV Transmission Is Falling Steadily in United Kingdom (May 1, 2007)
From aidsmap.com
- Emergence of Drug Resistance and First-Line Combination Therapy in the Swiss HIV Cohort Study (February 26, 2007)
To view original study poster, click here (PDF).
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- HIV Drug Resistance Common Among Recently Infected MSM: An Interview With Susan H. Eshleman, M.D., Ph.D., Johns Hopkins University (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- More Than 10% of U.S. Patients in 11 U.S. States With Either Newly or Recently Acquired HIV May Harbor Resistant Virus (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Incidence of Multidrug-Resistant Virus Appears to Be Declining in the HAART Era (November 14, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
- Higher Degree of Medication "Forgiveness" in Use of Boosted Protease Inhibitors (August 15, 2006)
In The XVI International AIDS Conference
- HIV JournalView: Adherence, Viral Fitness and NNRTI and PI Resistance (February/March 2006)
Bangsberg et al find that NNRTIs are more likely to suppress HIV than a single PI, but are also more vulnerable to resistance at low adherence levels.
From The Body PRO
- More Sensitive Drug-Resistance Tests Yield Higher Rates of Multidrug Resistance in Treatment-Naive Patients (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- Transmission of Multidrug-Resistant HIV Will Not Become More Frequent in United Kingdom Through 2010, Statistical Model Suggests (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- HIV JournalView: Low-Level Viremia May Slowly Breed Resistance, but Watch Out for NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
|
|
Advertisement
|
E-Mail
Glossary
Share
